Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

The most common side effects of GLP-1 medicines are related to digestion: nausea, vomiting, diarrhoea, indigestion, stomach ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic burden associated with SGAs. By intervening during the initial stages of ...

The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, ...

Metropolis Healthcare has launched three TruHealth GLP-1 test packages to monitor patients before and during obesity treatment as diagnostic firms target the growing GLP-1 therapy market in India ...